Search results for "Respiratory medicine"

showing 10 items of 1534 documents

Comparison of risk assessment strategies for not-high-risk pulmonary embolism

2015

We compared the prognostic performance of the 2014 European Society of Cardiology (ESC) risk stratification algorithm with the previous 2008 ESC algorithm, the Bova score and the modified FAST score (based on a positive heart-type fatty acid-binding protein (H-FABP) test, syncope and tachycardia, modified using high-sensitivity troponin T instead of H-FABP) in 388 normotensive pulmonary embolism patients included in a single-centre cohort study.Overall, 25 patients (6.4%) had an adverse 30-day outcome. Regardless of the score or algorithm used, the rate of an adverse outcome was highest in the intermediate-high-risk classes, while all patients classified as low-risk had a favourable outcome…

MalePulmonary and Respiratory MedicineTachycardiamedicine.medical_specialty030204 cardiovascular system & hematologyFatty Acid-Binding ProteinsRisk AssessmentSyncope03 medical and health sciences0302 clinical medicineRisk FactorsTachycardiaInternal medicineOdds RatiomedicineHumansProspective StudiesProspective cohort studyAgedTroponin Tbusiness.industryArea under the curveOdds ratioMiddle AgedPrognosismedicine.disease3. Good healthPulmonary embolismROC Curve030228 respiratory systemCohortCardiologyRegression AnalysisFemalemedicine.symptomPulmonary EmbolismbusinessRisk assessmentFatty Acid Binding Protein 3AlgorithmsEuropean Respiratory Journal
researchProduct

In vitro study of human alveolar macrophage and peripheral blood mononuclear cell reactive oxygen-intermediates release induced by sulfur dioxide at …

1994

Sulfur dioxide (SO2) is a major air pollutant in urban areas. Alveolar macrophages (AM) located on the alveolar surface are in direct contact with this inhaled gas. We evaluated the dose-dependent effect of SO2 exposure on the oxidative metabolism of AM and peripheral blood mononuclear cells (PBMNC) by measuring the spontaneous and stimulated reactive oxygen intermediates (ROI) release. AM or PBMNC were placed on a polycarbonate membrane, which was in direct contact with the surface of a nutrient reservoir. For exposure of the cells to SO2 a special chamber was employed, in which humidified standard air with 5% CO2 at 37 degrees C was mixed with SO2 at the desired concentration. Periods of …

MalePulmonary and Respiratory MedicineTime Factorschemistry.chemical_elementStimulationIn Vitro Techniquescomplex mixturesOxygenPeripheral blood mononuclear cellchemistry.chemical_compoundMacrophages AlveolarHumansSulfur DioxideIn vitro studyCells CulturedSulfur dioxidePollutantChromatographyDose-Response Relationship DrugChemistryMiddle Agedrespiratory tract diseasesLuminescent MeasurementsImmunologyLeukocytes MononuclearAlveolar macrophageFemaleReactive Oxygen SpeciesBronchoalveolar Lavage FluidPolycarbonate membraneLung
researchProduct

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with mod…

2015

Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o…

MalePulmonary and Respiratory MedicineVital capacitymedicine.drug_classChronic Obstructive Pulmonary DiseaseVital CapacityScopolamine DerivativesQuinolonesCOPD PharmacologyDrug Administration SchedulePulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodQuality of lifeForced Expiratory VolumeFormoterol FumarateBronchodilatorHumansMedicine1506Tiotropium BromideAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryMiddle Agedmedicine.diseaseGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeEthanolaminesBronchodilator AgentsAnesthesiaIndansQuality of LifeIndacaterolFemaleFormoterolbusinessmedicine.drugThorax
researchProduct

Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease

2008

SummaryBackgroundEpidemiologic studies have demonstrated that elderly patients with fixed airflow obstruction can be affected by asthma or chronic obstructive pulmonary disease (COPD).MethodsWe studied 49 consecutive elderly outpatients, presenting fixed airflow obstruction, by clinical history (smoking), pulmonary function tests, blood gas analysis, and induced sputum.ResultsThe age was not different in patients with COPD (n=28) and asthma (n=21) (70.2±3.9 years vs. 69.6±3.7 years), also the degree of fixed airflow obstruction was similar (FEV1: 58.3±1.5% vs. 59.0±1.4% of predicted). Patients with asthma had significantly more eosinophils in peripheral blood (0.43±0.05×10−3μL vs. 0.27±0.1×…

MalePulmonary and Respiratory MedicineVital capacitymedicine.medical_specialtySettore MED/09 - Medicina Internaasthma chronic obstructive pulmonary disease.NeutrophilsVital Capacitychronic obstructive pulmonary disease.GastroenterologyPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioElderlyDLCOForced Expiratory VolumeInternal medicinemedicineHumanselderly patients; fixed airflow obstruction; asthma; chronic obstructive pulmonary disease.AgedAsthmaCOPDEosinophil cationic proteinbusiness.industryChronic obstructive pulmonary diseasefixed airflow obstructionRespiratory diseaseSputumasthmamedicine.diseaseRespiratory Function Testselderly patientrespiratory tract diseasesSurgeryEosinophilsFemalebusinessRespiratory Medicine
researchProduct

Sensitization in early age to food allergens in children with atopic dermatitis

2007

Background: Clinical and laboratory evidence increasingly supports the notion that food allergy plays a role in the pathogenesis of atopic dermatitis (AD). However, the prevalence of clinically significant food hypersensitivity among children with AD remains an unanswered question. Objective: To prospectively determine the prevalence of IgE-mediated food hypersensitivity among patients referred to a dermatology department for evaluation of AD, and to analyze the clinical relevance of these sensitizations in AD. Methods: We studied 44 infants of both sexes, aged less than 12 months old, who attended the dermatology department with symptoms of AD. Compliance with Hanifin-Rajka criteria was co…

MalePulmonary and Respiratory Medicinefood hypersensitivitymedicine.medical_specialtyEggsImmunologyEgg Proteins DietarySeverity of Illness IndexDermatitis Atopicfood challengeAntibody SpecificityFood allergyElimination dietPrevalencemedicineAnimalsHumansImmunology and AllergyClinical significanceProspective StudiesAge of OnsetFood allergensSensitizationSkin Testsfood allergyatopic dermatitisbusiness.industryInfantegg allergyGeneral MedicineAtopic dermatitisAllergensImmunoglobulin EMilk Proteinsmedicine.diseaseFood hypersensitivityDermatologycow's milk allergymedicine.anatomical_structureEgg allergyCattleFemaleInfant FoodMilk HypersensitivitybusinessChickensFood Hypersensitivity
researchProduct

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

2021

Background: Aspiration community-acquired pneumonia (ACAP) and community-acquired pneumonia (CAP) in patients with aspiration risk factors (AspRFs) are infections associated with anaerobes, but limited evidence suggests their pathogenic role. Research Question: What are the aspiration risk factors, microbiology patterns, and empiric anti-anaerobic use in patients hospitalized with CAP? Study Design and Methods: This is a secondary analysis of GLIMP, an international, multicenter, point-prevalence study of adults hospitalized with CAP. Patients were stratified into three groups: (1) ACAP, (2) CAP/AspRF+ (CAP with AspRF), and (3) CAP/AspRF- (CAP without AspRF). Data on demographics, comorbidi…

MalePulmonary and Respiratory Medicinemedicine.drug_classAspiration riskAntibioticsNursing home residentSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineMicrobiologyanaerobic; aspiration; bacteria; pneumonia; risk factors.Cohort Studies03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaTaverneAnti-Bacterial AgentmedicineHumanspneumoniarisk factors.Community-Acquired Infection030212 general & internal medicinebacteriaStrokeAgedAged 80 and overaspirationbusiness.industryRespiratory AspirationMiddle Agedmedicine.diseaseAntibiotic coverageAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumonia030228 respiratory systemRisk factorsrisk factoranaerobicFemaleUnderweightmedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

Oral Sustained-Release Aminophylline and Bronchodilator Response to Inhaled Fenoterol in Patients with Chronic Airflow Obstruction

1985

The bronchodilator response to inhaled fenoterol (400 micrograms) was examined in the morning and in the afternoon before and during oral sustained-release aminophylline treatment in eight patients with chronic reversible airway obstruction. Bronchodilatation was evaluated by measuring serial peak expiratory flow rates (PEFR) for eight hours after inhaled fenoterol and calculating the area under the time-response curves and the percentage increment from the baseline values. The patients showed an enhancement of the bronchodilatation achieved with fenoterol in the morning during aminophylline treatment. In the afternoon, instead, the effect of the fenoterol was not improved by oral aminophyl…

MalePulmonary and Respiratory Medicinemedicine.drug_classPeak Expiratory Flow RateCritical Care and Intensive Care MedicineBronchodilatormedicineHumansLung Diseases ObstructiveFenoterolFenoterolMorningAerosolsInhalationbusiness.industryRespiratory diseaseMiddle Agedrespiratory systemAirway obstructionmedicine.diseaseAminophyllineBronchodilator AgentsBronchodilatationDelayed-Action PreparationsAnesthesiaDrug Therapy CombinationFemaleAminophyllineCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD

2000

ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD.Eighty patients with well-controlled COPD were randomized to receive 3 months of treatment in one of four treatment groups: (1) salmeterol, 50 microg bid; (2) salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid; (3) salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid; and (4) salmeterol, 50 microg, plus titrated theophylline bid. At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg.A gradual increase in FEV(1) was observed with each …

MalePulmonary and Respiratory Medicinemedicine.drug_classPharmacologyCritical Care and Intensive Care MedicineFluticasone propionateTheophyllineForced Expiratory VolumeBronchodilatorAdministration InhalationmedicineHumansAlbuterolTheophyllineLung Diseases ObstructiveGlucocorticoidsSalmeterol XinafoateAgedFluticasoneDose-Response Relationship Drugbusiness.industryDrug SynergismAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerBronchodilator AgentsAndrostadienesAnesthesiaSalbutamolFluticasoneCorticosteroidDrug Therapy CombinationFemaleSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

2011

SummaryBackgroundIndacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the treatment of COPD.MethodsThis 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD. Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea index (TDI) and rescue medication use.ResultsOf 1123 patients randomised 92.1% completed. Mean ± SD age was 62.8 ± 8.78 years, p…

MalePulmonary and Respiratory Medicinemedicine.drug_classbeta2-agonistQuinolonesDrug Administration Schedulelaw.inventionFEV1/FVC ratioPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawBronchodilatorForced Expiratory VolumeClinical endpointmedicineCOPDHumansAlbuterolSalmeterolSalmeterol XinafoateIndacaterolCOPDDose-Response Relationship Drugbusiness.industryrespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsRespiratory Function TestsTreatment OutcomeAnesthesiaIndansIndacaterolFemaleSalmeterolOnce dailybusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct

Is Endocan a Diagnostic Marker for Pneumonia After Cardiac Surgery? The ENDOLUNG Study

2017

Background Postoperative pneumonia is frequent after cardiac surgery and is associated with increased morbidity and mortality. We tested the hypothesis that endocan is an early biomarker for the detection of pneumonia after cardiac surgery. Methods Between January and May 2016, 155 patients scheduled to undergo elective cardiac surgery with cardiopulmonary bypass were prospectively included in the study. Serum level of endocan was measured at five timepoints (preoperative, and at 6, 24, 48, and 72 hours after the end of surgery). Procalcitonin and C-reactive protein were measured at 24 and 72 hours. The preoperative and postoperative characteristics of the patients were recorded. Independen…

MalePulmonary and Respiratory Medicinemedicine.medical_specialty030204 cardiovascular system & hematologyProcalcitoninlaw.invention03 medical and health sciencesPostoperative Complications0302 clinical medicinelawmedicineCardiopulmonary bypassHumansProspective StudiesCardiac Surgical ProceduresProspective cohort studyAgedbusiness.industry030208 emergency & critical care medicinePneumoniaMiddle Agedmedicine.diseaseNeoplasm ProteinsCardiac surgerySurgeryClinical trialPneumoniaROC CurveElective Surgical ProceduresAnesthesiaBiomarker (medicine)FemaleProteoglycansSurgeryCardiology and Cardiovascular MedicinebusinessBody mass indexBiomarkersFollow-Up StudiesThe Annals of Thoracic Surgery
researchProduct